"Alimera is pleased to share details of the Iluvien FAME study at this venue, perhaps the most important ophthalmology meeting of the year," said Dan Myers, Alimera president and CEO. "We believe the combination of low dose and long duration makes Iluvien a much anticipated potential treatment for DME."Alimera submitted the Iluvien New Drug Application (NDA) to the U.S. Food and Drug Administration on June 30, 2010, and based on receipt of Priority Review status in August, anticipates a communication regarding the NDA by the end of the year. In addition, Alimera submitted a Marketing Authorization Application on July 5, 2010 to the Medicines and Healthcare products Regulatory Agency in the United Kingdom. Applications have also been submitted to regulatory agencies in Austria, France, Germany, Italy, Portugal and Spain.
Alimera Sciences' FAME(TM) Study Data On Iluvien(R) To Be Presented At AAO 2010 Annual Meeting
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.